Company intelligence / Profile preview

MACAO G-RX

Ownership: Private
Development stage: Other

Overview

Macao G-RX is a biotechnology company based in Macau that focuses on the development of innovative therapies for metabolic diseases, including obesity and type 2 diabetes. The company leverages advanced research in incretin-based therapies, specifically targeting the GLP-1 and GIP receptors. Their pipeline includes next-generation small molecule and peptide-based candidates designed to improve metabolic health and weight management. Macao G-RX aims to bridge the gap between academic research and clinical application within the Greater Bay Area's growing life sciences ecosystem.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on MACAO G-RX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MACAO G-RX.